S&P 500 7522.53 -0.28%
NASDAQ 26060.62 -0.56%
TASI 10808.43 -0.42%
Oil (WTI) 71.83 -0.35%
Oil (Brent) 76.25 -0.07%
VIX 15.50 -2.15%
Gold 4115.00 -0.62%
USD/SAR 3.75 +0.01%

AbbVie Inc.

ABBV · Healthcare · · USD
246.19 USD
0.00 (-1.49%)
● Updated 2026-07-10 18:07 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Mid-term (Position)

75
/ 100
Technical 75
Trend & RS 90
Momentum 75
Fundamental 66
Macro 65
Liquidity 46
ComponentScoreWeight
Technical 75.0 20%
Trend & RS 89.5 30%
Momentum 74.9 15%
Fundamental 66.1 10%
Macro 65.2 20%
Liquidity 46.4 5%

Trade Setup

Entry 246.00
Stop Loss 232.88 (5.3%)
Target 1 (1:1) 259.12 (+5.3%)
Target 2 (2:1) 272.24 (+10.7%)
ATR(14) 6.56 (2.7%)
Risk per Share 13.12
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 23.4 -1.06
Momentum 74.9 +1.00
Quality 20.0 -1.20
Composite 39.5

Quality Scores

Piotroski F-Score 4 /9 — Average
✓ ✗ ✗ ✗ ✗ ✗ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 4.39 — Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 120.1 22.0 +446% above
P/B Ratio -65.3 4.0 Inline
Dividend Yield 2.8% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
39.15
vs
Market Price
246.19
Upside
-84.1%
Margin of Safety -528.8%
Stage 1 PV (5yr FCF)15,901,151,702
Terminal Value PV53,276,912,564
Total Enterprise Value69,178,064,266

Assumptions

Base FCF2,897,540,226
Growth Rate (5yr)12.4%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
48.74%
Full Kelly
24.37%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 75/100. Estimated win rate 63%, avg win 9.5%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
57.95
RSI(14)
8.7767
MACD

Relative Strength (RS) IMPROVING

73
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↑ RISING (+5.9% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (5d since high)
Sector Outperformance +11.3% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 57.95 NEUTRAL
Macd 8.7767 BEARISH
Ma Cross 223.88 / 220.64 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.13x LOW

Key Levels

LevelPrice
52-Week High261.64
Bollinger Upper269.01
SMA(200)220.64
SMA(50)223.88
SMA(20)240.33
Current Price246.19
Bollinger Lower211.64
52-Week Low184.63
ATR(14)6.56

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

DISTRIBUTION A Confidence
50%
Buying Climax
Acc: 0.0  |  Dist: 2.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-06 Normal 0.93x Normal bar — no special VSA pattern
2026-07-07 Normal 0.89x Normal bar — no special VSA pattern
2026-07-08 Normal 0.82x Normal bar — no special VSA pattern
2026-07-09 Normal 0.6x Normal bar — no special VSA pattern
2026-07-10 Normal 0.13x Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 253.77 Above Kijun
Kijun-sen (26) 237.69 Base line
Senkou A 245.73 Leading span A
Senkou B 226.19 Leading span B
Cloud 226.19 – 245.73 Bullish (Green)
Price vs Cloud 246.00 Above Cloud
Chikou Span 217.13 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 211.64 – 269.01  |  KC: 230.1 – 250.55

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bullish RSI 15
Regular Bearish RSI 19

Anchored VWAP

VWAP: 218.44 Anchor: 2025-07-21 (52w Low) ABOVE AVWAP +12.6%

Heikin-Ashi Trend

BEARISH Full data via /api/advanced/ABBV

Valuation

MetricValue
Market Cap434.97B
P/E (TTM)120.09
Forward P/EN/A
P/B-65.35
EPS2.05

Financial Health

MetricValue
Revenue Growth12.4%
Profit Margin5.8%
ROEN/A
Debt/EquityN/A
Current Ratio0.80
Dividend Yield2.8%
Payout RatioN/A
Beta0.28

Trading Data

246.19
Open
246.19
Day High
246.19
Day Low
1.15M
Volume (0.2x avg)

Recent News (8)

JNJ Stock Keeps Climbing. Should You Climb On?
Trefis · 2026-07-10
3 Psychedelic Stocks With Potential Clinical Trial Catalysts
Simply Wall St. · 2026-07-10
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
Zacks · 2026-07-09
Make Your AMGN Shares Pay You 8.7% While You Hold Them
Trefis · 2026-07-09
ABBV Leads Its Peer Group. You Pay For That
Trefis · 2026-07-09
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
Zacks · 2026-07-09
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY
Stocktwits · 2026-07-09
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
MT Newswires · 2026-07-08

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —